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Maternal Cell free DNA based screening for fetal microdeletion 
and the importance of careful diagnostic follow up
Svetlana A. Yatsenko, MD1, David Peters, PhD1, Devereux Saller, MD1, Tianjiao Chu, PhD1, 
Michelle Clemens, MS, CGC1, and Aleksandar Rajkovic, MD, PhD1
1Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Womens Research 
Institute, University of Pittsburgh, Pittsburgh, PA 15213
Abstract
Background—Noninvasive prenatal screening (NIPS) by next-generation sequencing of cell 
free DNA (cfDNA) in maternal plasma is used to screen for common aneuploidies such as trisomy 
21, in high risk pregnancies. NIPS can identify fetal genomic microdeletions, however sensitivity 
and specificity have not been systematically evaluated. Commercial companies have begun to 
offer expanded panels including screening for common microdeletion syndromes such as 22q11.2 
deletion (DiGeorge syndrome) without reporting the genomic coordinates or whether the deletion 
is maternal or fetal. Here we describe a phenotypically normal mother and fetus that tested 
positive for atypical 22q deletion via maternal plasma cell free DNA testing.
Methods—We performed cfDNA sequencing on saved maternal plasma obtained at 11 weeks of 
gestation from a phenotypically normal woman with a singleton pregnancy whose earlier 
screening at a commercial laboratory was reported to be positive for a 22q11.2 microdeletion. 
FISH and chromosomal microarray diagnostic genetic tests were done postnatally.
Conclusion—NIPS detected a 22q microdeletion that upon diagnostic work up, did not include 
the DiGeorge critical region. Diagnostic prenatal or postnatal testing with chromosomal 
microarray and appropriate parental studies to determine precise genomic coordinates and 
inheritance should follow a positive microdeletion NIPS result.
Introduction
Noninvasive prenatal screening (NIPS) has become available over the last few years and 
become increasingly requested in lieu of diagnostic procedures. Fetal aneuploidies such as 
trisomy 21 as well as chromosomal microdeletions can be identified by analysis of fetal cell-
free DNA (cfDNA) in the maternal plasma1–3. For many pregnant women the availability of 
NIPS offers more accurate option over the conventional prenatal methods for screening of 
fetal chromosomal abnormalities and removes the fear of miscarriage associated with 
invasive diagnostic testing. NIPS is currently offered exclusively through commercial 
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entities. Some commercial companies have begun to offer microdeletion testing for common 
conditions such as DiGeorge syndrome. DiGeorge or 22q11.2 deletion syndrome (MIM 
188400) affects 1 in 4,000 individuals and is associated with multiple anomalies including 
congenital heart disease, palatal defects, and immune deficiency. About 10% of 22q11.2 
deletions are inherited from a mildly affected parent. DiGeorge syndrome in infants 
commonly requires an acute management of hypocalcemia, surgery for conotruncal cardiac 
defects, and treatment of immunodeficiency. Therefore, prenatal detection plays an 
important role in pregnancy management and postnatal interventions. Here we present the 
clinical management and diagnostic testing initiated by positive NIPS screen for 22q 
deletion.
Methods
Patient was enrolled into the NIPS research study in our institution as part of quality control, 
under an IRB approved protocol. Maternal blood was obtained at 11 weeks of gestation and 
banked, independent of the blood sent to commercial lab as part of clinical care. cfDNA was 
extracted from maternal plasma and the whole genome sequencing of cfDNA was 
performed as previously described4 postnatally (Figure 1). Peripheral blood sample was 
obtained from the newborn child of the patient for confirmatory fluorescence in situ 
hybridization (FISH) and microarray analyses. FISH was completed using a commercial 
TUPLE1 (HIRA) assay (Vysis). A 180K CGH+SNP (SurePrint G3 ISCA design, Agilent) 
platform was used for microarray analysis according to the manufacturer’s protocol.
Results
A 40-year-old gravida 6, para 2 underwent noninvasive cfDNA testing in her private 
physician’s office for advanced maternal age. In addition to the negative aneuploidy result, 
the test was reported as positive for a fetal DiGeorge syndrome microdeletion. However, the 
report did not indicate genomic coordinates. The patient was counseled that the baby may be 
affected with DiGeorge syndrome and referred to tertiary care center at 18 weeks of 
gestation for fetal echocardiography and ultrasound screen. Prenatal ultrasound 
demonstrated no apparent anomalies. The location and volume of fetal thymus and fetal 
echocardiogram were normal. Fetal growth restriction was detected in the third trimester and 
likely related to chronic hypertension. The patient declined diagnostic genetic testing during 
pregnancy. Due to uncertainty of whether NIPS result was a true or false positive, and 
screening nature of the prenatal ultrasound, recommendation was made to deliver at a 
tertiary care center for detailed postnatal examination. She developed severe preeclampsia 
and delivered by repeat cesarean section at 32 weeks, 5 days of a 1053 grams male with 
Apgars of 8 and 9. The baby was discharged to home at 5 weeks of life. Physical 
examination did not reveal craniofacial abnormalities and postnatal echocardiogram did not 
identify heart defects. Because of the abnormal NIPS result, the DiGeorge critical region 
was evaluated by FISH for the commonly deleted region (chr22:19,318,224–19,419,219). 
No deletion was detected in this region. A chromosomal microarray on the newborn showed 
a 790 kb microdeletion on chr22:20,719,112–21,505,417(hg19) (Figure 1A–C). This 
deletion involves the distal part of the classical DiGeorge region (B–D atypical), which does 
not include the TBX1 gene, thought to be responsible for the DiGeorge syndrome 
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characteristic craniofacial features and heart malformations5. Microarray analysis on 
parental samples showed that the deletion was inherited from the mother, whose physical 
and echocardiographic examination was unremarkable. The repeated whole-genome 
sequencing in our academic laboratory of maternal plasma DNA, obtained at 11 weeks 
gestation, discovered that coordinates of the deleted region match closely those found by 
microarray (Figure 1D).
Discussion
Non-invasive prenatal screening is currently offered as an alternative to serum screening 
programs based on protein and hormone markers for high-risk pregnancies due to its 
superiority in detecting trisomy 212,6–8. Moreover, societies such as American College of 
Obstetrics and Gynecology support its use in high risk patients9. Despite some advantages, 
NIPS is a screening test. The recent addition of microdeletion detection involving 4p, 5p, 
15q12, 22q11 and other regions, marks an attempt by commercial companies to show the 
feasibility of identifying pathogenic microdeletions, as well as differentiate from each other. 
Although NIPS can be used to uncover fetal microdeletions, positive results have been 
described in few cases1–3. The accurate detection of microdeletions requires higher number 
of sequencing reads, and its sensitivity and specificity are still unknown. An argument can 
be made that routine NIPS microdeletion screening at this time is premature and should only 
be offered under a research protocol, until we understand its true sensitivity, specificity, 
technical and biological variables that impact the detection accuracy, and relevance to 
phenotypic penetrance. Nonetheless, we have seen that general clinicians have begun to 
offer deletion screening in addition to aneuploidy testing. Fetal fraction constitutes 10% or 
less of the maternal plasma3, which makes it difficult to differentiate whether the deletion is 
fetal or maternal, or both. Positive deletion testing on NIPS should be followed by 
diagnostic testing to confirm the fetal origin of the deletion as well as parental studies to 
establish inheritance and to provide accurate counseling for conditions with variable 
expressivity and incomplete penetrance. Moreover, in the absence of precise genomic 
coordinates, it is difficult to counsel phenotypic consequences of a particular genotype, as 
deleted gene content is not reported. In our case, the family lived in rural area, 
approximately 3 hours away from the tertiary care center. Due to NIPS findings, our patient 
underwent multiple fetal ultrasound visits before her care was transferred to the tertiary care 
center for closer monitoring, but at increased cost to the patient due to transportation, time 
spent and delivery away from home. In our case, both the patient and her child were found 
to carry atypical small 22q11.2 deletion that did not include the DiGeorge critical region. 
Deletions of this region have been associated with a variable phenotype and incomplete 
penetrance. The exact genomic coordinates of the abnormality would be extremely valuable 
for optimized prenatal management, accurate genetic counseling of our patient, and 
appropriate diagnostic postnatal testing. With an increased use of NIPS in prenatal 
diagnosis, and current shift to also reporting microdeletions, it is of great importance to have 
precise genomic coordinates in order to determine affected gene content, and to 
appropriately counsel the patient. When NIPS report detects a fetal deletion, it is essential to 
counsel the mother that she is at risk of having the deletion and to perform diagnostic 
evaluation on the trio of fetus, mother and father for the origin of the genomic alteration. 
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NIPS, whether for aneuploidy or copy number variant identification is a screening test and 
always warrants further counseling with an offer of additional diagnostic studies.
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Figure 1. 
A. Schematic presentation of the DiGeorge critical region on the proximal long arm of 
chromosome 22. The location of the LCR22-A, LCR22-B, LCR22-C and LCR22-D repeats 
are shown as blue boxes. Arrowhead represents the location and orientation of the TBX1 
gene transcription. B. The common ~2.6 – 3 Mb deletion (~85% of patients with DiGeorge/ 
Velocardiofacial syndrome) occurs between the LCR22-A and LCR22-D repeats (A–D 
deletion) and includes TBX1. An array CGH plot from an individual with a standard A–D 
deletion is shown. Each dot represents an oligonucleotide probe arranged according to their 
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physical map locations from the proximal (left) to the distal (right) long arm of the 
chromosome 22 (X-axis), placed on a log2 scale (Y-axis). At the bottom, genomic 
coordinates (in megabases, Mb) are given according to the Human Genome Browser map 
(GRCh37/hg19). Black dots indicate DNA probes with normal copy number (log2 is 
between +0.3 and −0.5). Red dots designate chromosomal segment with a negative log2 ratio 
(below −0.5), depicting the deletion region. C. Array-CGH plot from the newborn baby 
showing an atypical deletion of the DiGeorge region with the breakpoints between LCR22-
B and LCR22-D repeats (blue double arrowhead). The B–D deletion does not involve TBX1, 
and therefore cannot be detected by the commercially available FISH probes. D. Maternal 
plasma at 11 weeks of gestation was used to isolate and whole genome sequence cell free 
DNA1. Relative difference between the observed tag count in part of chromosome 22 in the 
patient’s sample and the expected tag count for a normal sample was performed as 
previously described4. The whole genome sequencing of cell free DNA shows a deletion 
between 20.75 and 21.485 Mb, which corresponds to the array CGH findings.
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